Annual Working Capital
$240.26 M
+$172.22 M+253.12%
December 31, 2023
Summary
- As of February 7, 2025, ELVN annual working capital is $240.26 million, with the most recent change of +$172.22 million (+253.12%) on December 31, 2023.
- During the last 3 years, ELVN annual working capital has risen by +$111.15 million (+86.09%).
- ELVN annual working capital is now at all-time high.
Performance
ELVN Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Working Capital
$279.97 M
-$16.05 M-5.42%
September 30, 2024
Summary
- As of February 7, 2025, ELVN quarterly working capital is $279.97 million, with the most recent change of -$16.05 million (-5.42%) on September 30, 2024.
- Over the past year, ELVN quarterly working capital has dropped by -$32.20 million (-10.31%).
- ELVN quarterly working capital is now -10.31% below its all-time high of $312.17 million, reached on March 31, 2024.
Performance
ELVN Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Working Capital Formula
Working Capital = Current Assets − Current Liabilities
ELVN Working Capital Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +253.1% | -10.3% |
| 3 y3 years | +86.1% | -2.5% |
| 5 y5 years | +86.1% | -2.5% |
ELVN Working Capital Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +253.1% | -10.3% | +311.5% |
| 5 y | 5-year | at high | +253.1% | -10.3% | +311.5% |
| alltime | all time | at high | +253.1% | -10.3% | +311.5% |
Enliven Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $279.97 M(-5.4%) |
| Jun 2024 | - | $296.02 M(-5.2%) |
| Mar 2024 | - | $312.17 M(+29.9%) |
| Dec 2023 | $240.26 M | $240.26 M(-6.3%) |
| Sep 2023 | - | $256.53 M(-6.4%) |
| Jun 2023 | - | $274.03 M(-4.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2023 | - | $287.06 M(+321.9%) |
| Dec 2022 | $68.04 M(-35.2%) | $68.04 M(-14.8%) |
| Sep 2022 | - | $79.90 M(-23.8%) |
| Dec 2021 | $104.92 M(-18.7%) | - |
| Dec 2021 | - | $104.92 M |
| Dec 2020 | $129.11 M | - |
FAQ
- What is Enliven Therapeutics annual working capital?
- What is the all time high annual working capital for Enliven Therapeutics?
- What is Enliven Therapeutics annual working capital year-on-year change?
- What is Enliven Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Enliven Therapeutics?
- What is Enliven Therapeutics quarterly working capital year-on-year change?
What is Enliven Therapeutics annual working capital?
The current annual working capital of ELVN is $240.26 M
What is the all time high annual working capital for Enliven Therapeutics?
Enliven Therapeutics all-time high annual working capital is $240.26 M
What is Enliven Therapeutics annual working capital year-on-year change?
Over the past year, ELVN annual working capital has changed by +$172.22 M (+253.12%)
What is Enliven Therapeutics quarterly working capital?
The current quarterly working capital of ELVN is $279.97 M
What is the all time high quarterly working capital for Enliven Therapeutics?
Enliven Therapeutics all-time high quarterly working capital is $312.17 M
What is Enliven Therapeutics quarterly working capital year-on-year change?
Over the past year, ELVN quarterly working capital has changed by -$32.20 M (-10.31%)